iWOW Technology Limited Announces Strategic Acquisition of The Gentle Group Pte. Ltd.

Key Highlights Investors Need to Know

• Acquisition of 100% Interest in The Gentle Group: iWOW Technology Limited (“iWOW”) has entered into a Sale and Purchase Agreement (SPA) to acquire 100% of the issued and paid-up shares and option shares of The Gentle Group Pte. Ltd. (“The Gentle Group”), a clinical nutrition and therapeutic meals provider focused on the senior and healthcare markets in Singapore.
• Transaction Value and Structure: The aggregate consideration for the acquisition is S\$11.2 million, to be paid via a combination of cash (to institutional and minority vendors, and option holders) and issuance of new iWOW shares (to the Founder, Dr. Shen Yiru).
• Discloseable Transaction: The deal qualifies as a “discloseable transaction” under SGX Catalist Rules. Shareholder approval is NOT required as the relative figures for the acquisition do not cross 75% on any test, but do exceed 5%—making this announcement price sensitive.
• Founder Retention and Management Continuity: Dr. Shen Yiru will remain as head of The Gentle Group post-acquisition, ensuring business continuity and alignment with iWOW’s strategic objectives.
• Strategic Rationale: The acquisition transforms iWOW from a focused AgeTech provider to a key participant in the broader longevity economy, leveraging The Gentle Group’s clinical nutrition expertise with iWOW’s technology and AI-driven platforms.
• Significant Expansion Plans: The Gentle Group is currently operating at full production capacity. iWOW will support a major expansion plan, including a new facility to scale up production capacity by approximately five times.
• Strong Financial Undertaking: iWOW will provide up to S\$5 million in financial support for The Gentle Group’s expansion, including an immediate S\$2 million by 30 June 2026, with the balance provided as needed for growth and operational requirements.
• Lock-up and Non-Compete Clauses: The Founder must not sell or transfer her new iWOW shares for three years, and is subject to stringent non-compete and non-solicitation undertakings for up to 60 months.
• Vendor and Employee Protection: The Company is restricted from undertaking any restructuring, retrenchment, or material changes affecting The Gentle Group’s business without Founder consent for three years post-completion.

Detailed Overview of the Acquisition

Background and Terms

iWOW has signed an SPA on 30 April 2026 with The Gentle Group’s founder, institutional investors (Heritas Venture Fund, Heritas Capital VCC, Seeds Capital), minority shareholders, and option holders. The SPA covers the acquisition of 90,000 ordinary shares and 79,568 preference shares (100% equity), as well as all vested option shares.

The agreed consideration of S\$11.2 million will be satisfied as follows:

• S\$5,612,215.98 in cash to institutional vendors at completion.
• S\$4,847,031.85 to the Founder, comprising S\$1 million initial cash, S\$2,847,031.85 via 8,924,865 new iWOW shares (issued at S\$0.319/share), and S\$1 million deferred cash subject to a 20% revenue growth KPI for the period 1 April 2026 to 31 March 2027.
• S\$84,471.55 in cash to minority shareholders at completion.
• S\$342,201.15 in cash to option holders (excluding the Founder, whose option payout is included above), based on a cashless exercise formula.

Strategic Rationale and Price-Sensitive Implications

• Market Positioning: This acquisition positions iWOW to deepen its reach in the longevity economy, addressing seniors’ needs across safety, health, and daily living.
• Revenue Diversification: Integration adds a stable, contract-driven recurring revenue stream from The Gentle Group’s core institutional business, supporting earnings visibility and cash flow stability.
• Synergy Opportunities: iWOW will cross-leverage its technology with The Gentle Group’s clinical nutrition and food distribution channels, unlocking new B2B and B2C go-to-market strategies.
• Expansion Funding Assurance: iWOW’s commitment to inject at least S\$5 million for expansion, including a S\$2 million tranche by 30 June 2026, is a concrete growth catalyst.
• Founder and Key Management Retention: Ensures stability and continuity, mitigating key-person risk.
• Pro-Shareholder Protections: Founder gets veto rights on major business changes for three years, and lock-up agreements ensure alignment of interests.

Financial Effects and Potential Share Price Impact

• NTA Per Share: The pro forma Net Tangible Assets (NTA) per share will decrease from 5.66 cents to 3.28 cents, primarily due to recognition of S\$8.8 million in goodwill.
• Earnings Per Share (EPS): Pro forma loss per share narrows from (0.69) to (0.60) Singapore cents, reflecting the initial modest profit contribution from The Gentle Group.
• Relative Figures: The deal size is significant (11.4% of market cap, 21.3% of net profit), but not large enough to trigger shareholder approval—nonetheless, it is price sensitive as it materially alters the group’s business profile and financials.
• Consideration Shares: The 8,924,865 new iWOW shares issued (3.2% of existing share capital) do not trigger a change-of-control event but result in some dilution.

Risk Factors and Shareholder Considerations

• Completion Risk: The deal is subject to a number of conditions precedent, including SGX approval for new shares, customer/vendor consent, and satisfactory due diligence. There is no guarantee of completion.
• Integration Risk: Success depends on effective post-merger integration, and continued performance of The Gentle Group.
• Financial Support Commitment: iWOW is committed to substantial new investment in The Gentle Group’s expansion, which could impact iWOW’s cash flows and funding requirements.
• Lock-up and Non-Compete: The Founder is restricted from selling her new iWOW shares for three years and must not compete in the clinical nutrition space for up to five years, securing alignment with iWOW’s long-term strategy.

Other Noteworthy Points

• No Director or Controlling Shareholder Interest: No iWOW director or controlling shareholder has any direct or indirect interest in the acquisition.
• Inspection of SPA: The SPA is available for inspection at iWOW’s registered office for three months (by appointment).
• Trading Advisory: Investors are cautioned that completion is subject to conditions, and should exercise caution in trading iWOW shares.

Conclusion

This acquisition is a material and strategic move for iWOW Technology Limited, expanding its business model into the rapidly growing longevity economy. The deal is designed to create long-term value through recurring revenues, product and technology synergies, and a major capacity and market expansion. However, the transaction’s completion is subject to a number of conditions, and there are dilution and integration risks investors should consider. Overall, this is a price-sensitive development and could have a significant impact on iWOW’s share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation. Investors should carefully read official company disclosures and consult their professional advisers before making any investment decisions. The information herein is based on company announcements and may be subject to change or completion risks.

View iWOW Tech Historical chart here